Avive Solutions Secures $56.5M in Series B Funding to Revolutionize Defibrillator Technology and Save More Lives

Avive Solutions Inc., the Bay Area-based MedTech innovator known for its award-winning, next-generation automated external defibrillator (AED) and software solutions, is thrilled to announce that it has successfully raised $56,500,000 in its latest funding round. This substantial investment reflects the growing confidence of venture capitalists in Avive’s mission to revolutionize the way sudden cardiac arrests are managed and to significantly increase survival rates. The funds will accelerate further advancements in its patented technology—the only AED in the industry with the capability to automatically alert 911—reinforcing its status as a life-saving tool that bridges critical gaps in emergency care. As an FDA-approved company, Avive Solutions is uniquely positioned at the intersection of technology and healthcare innovation. The capital infusion will support both the expansion of its state-of-the-art product portfolio and the scaling up of operations to meet soaring market demand. Moreover, the funding will be strategically deployed to enhance the software aspects of its offering, ensuring that the integration of smart diagnostics and connectivity features continues to optimize emergency response times. This initiative is poised to transform public health outcomes by enabling faster, more accurate responses in critical situations. Avive Solutions is excited to leverage this financial boost to further its vision of saving lives by providing communities with cutting-edge, reliable, and accessible lifesaving technology. Join us on our journey to reshape the future of emergency medical care and help us deliver hope when every second counts.